ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMajor neurocognitive disorder (MNCD) represents a critical public health crisis. From the two waves of the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia, we investigated the predictive power of longitudinal alterations in plasma proteins to predict the progression from mild cognitive impairment (MCI) to MNCD in India.
methodsThis prospective cohort followed 4635 participants over 55 months. Plasma levels of amyloid beta (Aβ) 42/Aβ40 ratio, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau phosphorylated at threonine 181 (pTau181), and total tau (t-tau) were measured via single molecule array technology. Comprehensive geriatric assessments were conducted, and Clinical Dementia Rating (CDR) scores were measured.
resultsAs participants progressed from MCI to MNCD, significant declines in cognitive and functional parameters coincided with elevated plasma protein levels. Biomarkers (GFAP, NfL t-tau, and pTau181) demonstrated strong predictive accuracy, with area under the curve values of 81%, 71%, 74%, and 67%, respectively. DISCUSSION: Plasma biomarkers effectively estimate dementia progression rates. These findings support using blood-based markers to monitor and track disease trajectory in the Indian population, offering significant clinical utility for early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.